PharmiWeb Recruiter Blog

• Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines.
• Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London.
• Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines.
• Expansion follows recent acceptance of a Drug Master File and first investigational new drug application using doggybone DNA.

Hampton, UK, 24 May 2023 – Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the River Thames.

• Global biopharmaceutical services provider Allucent has partnered with THREAD, an innovative decentralized clinical trial (DCT) and eCOA technology provider, to launch Allucent Patient Direct Trials, a DCT offering focused on small and mid-sized biotech companies.
• Allucent Patient Direct Trials provides small and mid-sized biotech companies with access to advanced technologies, operational experience, and regulatory expertise to design and execute more patient-focused trials and realize the efficiencies of a DCT approach.
• The announcement coincides with the 2023 World Orphan Drug Congress, where Allucent will lead a panel session on the value of decentralized study designs and protocol optimization, especially for rare disease therapeutic development. 

CARY, N.C., May 23, 2023 – Global biopharmaceutical services provider Allucent announced today that it has partnered with THREAD, an innovative DCT and eCOA technology provider, to launch Allucent Patient Direct Trials. The new offering brings advanced technologies and development and regulatory expertise to small and emerging biotechnology companies to support them in designing and overseeing customized decentralized clinical trial approaches that address their needs.

• The Oxford-based company has relocated to the landmark Seacourt Tower in Botley, upgrading its office space to accommodate its growing team of AI specialists

OXFORD, UK, 15 May 2023 – Brainomix, the AI-powered medtech solutions company, today announced it has moved to a new head office in Oxford, located in the landmark Seacourt Tower in Botley.

• New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
• Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
• The new programs build on a successful first year of the multi-million-dollar corporate initiative

ABBOTT PARK, Ill., May 11, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

• Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology
• Advancing the use of bicycle peptides as a novel targeting approach in radiopharmaceuticals
• Bicycle Therapeutics to receive upfront payment of USD 45 million, and potential future development and commercial-based milestones, up to a total of USD 1.7 billion, plus tiered commercial royalties

BERLIN & CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bayer and Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle^®), today announced that they have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets.

– Acquisition of XinThera Provides Gilead with Precision Small Molecules Focused on PARP1 and MK2 Inhibitors –

• Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business...

Global Bayer Co.Lab network of life science incubators established to accelerate innovation and foster collaborations within vibrant biotech ecosystems / U.S. flagship location opening in Cambridge, MA, encompasses state-of-the-art laboratories and collaborative working space designed specifically to support entrepreneurs focused on developing the next generation of cell and gene therapies / Bayer’s Co.Lab Cambridge co-located with the Bayer Research and Innovation Center (BRIC), BlueRock Therapeutics, and Leaps by Bayer, allowing for direct access to Bayer’s experts / Investment part of Bayer’s continued strategic investment in the U.S.

• The Institute of Human Biology aims to better predict which drug candidates are safe and most effective in patients by evolving and increasing the use of human model systems.
• Human model systems are miniature living 'replicas' of human tissues and organs that also have the potential to reduce reliance on animal testing.
• The institute brings together scientists from academia and industry to lead the broad adoption of human model systems in pharmaceutical R&D as well as in clinical practice.

Basel, 4 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the Institute of Human Biology (IHB) focussing on advancing research in the field of human model systems such as organoids. Leveraging human model systems, the institute aims to accelerate drug discovery and development by improving the understanding of how organs function and how diseases develop. Ultimately, this will help to bring medicines to patients faster. These efforts will also enable early testing of which drug candidates are safe and which molecules would work best for each patient.

National Biotechnology Company Adds New Location in Louisiana